Mannatech AI Stock Analysis
Want to see MTEX full AI Analyst Report?
Mannatech (MTEX) AI Stock Analysis
Mannatech
(NASDAQ:MTEX)
The overall score is at the lowest possible level, reflecting a high-risk profile. The most significant factor is the company's severely deteriorated financial health, marked by persistent revenue declines, negative cash flow, and a recently insolvent balance sheet. This is compounded by deeply bearish technicals, with the stock in a sustained downtrend and oversold conditions, and a negative P/E ratio that underscores the lack of current profitability.
Mannatech (MTEX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $7.26M
- Dividend Yield
- ―
- Average Volume (3M)
- 36.07K
- Price to Earnings (P/E)
- -12.9
- Beta (1Y)
- 0.58
- Revenue Growth
- -6.65%
- EPS Growth
- 64.09%
- Country
- US
- Employees
- 170
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Food Distribution
Mannatech Business Overview & Revenue Model
Company Description
Mannatech, Incorporated operates as a global enterprise focused on health and wellness. The company specializes in the creation, marketing, and distribution of a diverse range of products, including dietary supplements, topical skincare and anti-agin...
Mannatech Financial Statement Overview
Summary
Financial performance is critically weak. Revenue has persistently declined, the company swung to a net loss, and the balance sheet was recently insolvent with negative equity. Cash flow is negative, indicating the business is consuming cash. The TTM period shows only tentative stabilization from a very low base.
Income Statement
35NegativeBalance Sheet
18Very NegativeCash Flow
22Negative| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 103.07M | 108.04M | 117.87M | 131.96M | 137.21M | 159.76M |
| Gross Profit | 77.98M | 80.96M | 91.46M | 102.86M | 104.15M | 125.61M |
| EBITDA | 1.83M | -1.39M | 5.55M | 498.00K | 1.15M | 10.61M |
| Net Income | -425.00K | -15.21M | 2.49M | -2.24M | -4.49M | 9.84M |
Balance Sheet | ||||||
| Total Assets | 27.90M | 29.99M | 36.06M | 41.21M | 49.13M | 59.63M |
| Cash, Cash Equivalents and Short-Term Investments | 5.42M | 6.18M | 11.40M | 7.73M | 13.78M | 24.18M |
| Total Debt | 6.29M | 7.36M | 6.69M | 5.71M | 6.21M | 1.83M |
| Total Liabilities | 22.70M | 35.22M | 27.44M | 30.72M | 34.95M | 35.21M |
| Stockholders Equity | 5.20M | -5.22M | 8.61M | 10.48M | 14.18M | 24.41M |
Cash Flow | ||||||
| Free Cash Flow | -648.00K | -4.32M | 1.96M | -3.12M | -3.66M | 10.12M |
| Operating Cash Flow | -204.00K | -2.96M | 2.26M | -2.37M | -2.60M | 10.77M |
| Investing Cash Flow | -444.00K | -1.35M | -285.00K | -747.00K | -1.06M | -650.00K |
| Financing Cash Flow | -288.00K | -561.00K | 1.96M | -1.90M | -4.33M | -9.29M |
Mannatech Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTEX, the sentiment is Negative. The current price of 2.83 is below the 20-day moving average (MA) of 7.88, below the 50-day MA of 7.77, and below the 200-day MA of 6.27, indicating a bearish trend. The MACD of -0.65 indicates Positive momentum. The RSI at 22.15 is Positive, neither overbought nor oversold. The STOCH value of 0.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MTEX.
Mannatech Risk Analysis
Mannatech disclosed 41 risk factors in its most recent earnings report. Mannatech reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksMannatech Peers Comparison
Overall Rating
SKIN54Neutral
EPC51Neutral
TKLF43Neutral
NUS41Neutral
MTEX37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| 54Neutral | $98.46M | -5.32 | -32.09% | ― | -4.41% | -51.42% | |
| 51Neutral | $1.31B | -24.92 | -3.53% | 2.11% | -10.21% | -310.40% | |
| 43Neutral | $5.71M | 0.82 | 1.71% | 15.10% | 77.22% | -89.32% | |
| 41Neutral | $191.30M | -0.81 | -34.83% | 6.11% | -15.27% | -318.35% | |
| 37Underperform | $7.26M | -12.89 | 16.12% | ― | -6.65% | 64.09% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MTEX | Mannatech Inc | 2.83 | -6.63 | -70.08% | |
| NUS | Nu Skin Enterprises | 3.78 | -5.41 | -58.86% | |
| EPC | Edgewell Personal Care Co | 27.97 | 11.03 | 65.09% | |
| SKIN | Beauty Health Company | 13.88 | -11.93 | -46.22% | |
| TKLF | Yoshitsu Co. Ltd. Sponsored ADR | 1.44 | -1.31 | -47.63% |
Mannatech Corporate Events
Mannatech Restores Nasdaq Compliance Through Swiss Tax Ruling
NeutralOn April 20, 2026, Mannatech received a notice from Nasdaq that it was not in compliance with the minimum $2.5 million stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, after reporting negative equity of $5.2 millio...
Mannatech Appoints Robert Toth as New Board Chairman
PositiveOn September 1, 2026, Mannatech announced the retirement of long-serving chairman J. Stanley Fredrick from its board of directors, following his August 26, 2026 notice to step down for personal reasons. Fredrick, who joined the board in 2001 and has...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
